ArticleHaematologica2014
The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.
Article in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.Blood advances · 2023Trial
- Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes- a retrospective matched-pairs analysis.Annals of hematology · 2025Article
- MDS patient registries - achievements and challenges.Annals of hematology · 2024Review
- Article
- Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes.JCO oncology practice · 2023Article
- Myelodysplastic Syndromes: New Methods of Diagnosis, Prognostication, and TreatmentDeutsches Arzteblatt international · 2023Review
- Article
- [The prognostic significance of pretransplantation evaluation of IPSS-R and WPSS in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes.Frontiers in oncology · 2022Article
- Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes.Annals of hematology · 2021Article
- Article
- Integrating patient-centered factors in the risk assessment of MDS.Hematology. American Society of Hematology. Education Program · 2019Review
- Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients.Blood cancer journal · 2019Article
- Review
- Gender disparity in the survival of patients with primary myelodysplastic syndrome.Journal of Cancer · 2019Article
- [Prognostic evaluation of comorbidities in patients with myelodysplastic syndrome].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- MDS prognostic scoring systems – past, present, and future.Best practice & research. Clinical haematology · 2015Review
- Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy.Stem cells and cloning : advances and applications · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.